These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 12776141)

  • 1. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 3. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 5. Russian fund steps up investments in innovative biotechs.
    Katsnelson A
    Nat Biotechnol; 2012 Jan; 30(1):9-11. PubMed ID: 22231078
    [No Abstract]   [Full Text] [Related]  

  • 6. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 7. Hybrid rigor mortis.
    Nat Biotechnol; 2003 Jun; 21(6):585. PubMed ID: 12776128
    [No Abstract]   [Full Text] [Related]  

  • 8. Hybrid vigor.
    Williams K
    Nat Biotechnol; 2003 Aug; 21(8):843. PubMed ID: 12894189
    [No Abstract]   [Full Text] [Related]  

  • 9. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 11. New biotech hubs may emerge as industry matures.
    Basu P
    Nat Biotechnol; 2003 Oct; 21(10):1123. PubMed ID: 14520385
    [No Abstract]   [Full Text] [Related]  

  • 12. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 13. The other side of being CFO.
    Benner K
    Fortune; 2012 Oct; 166(6):58. PubMed ID: 23072075
    [No Abstract]   [Full Text] [Related]  

  • 14. Let the chips fall where they may.
    Jacobs T
    Nat Biotechnol; 2003 Feb; 21(2):129. PubMed ID: 12560829
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 16. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 18. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 19. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotechs feel the pain.
    Ledford H
    Nature; 2009 Jan; 457(7226):136-7. PubMed ID: 19129814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.